|
|
Type of Company:
Type:
|
Company
|
Ownership: |
Publicly Traded (ABCL, NASDAQ) |
Company Size: |
100-499 Employees In BC (100-499 Total)
100-499 In BC (100-499 Total)
|
Year Founded: |
2012 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
AbCellera, drug discovery platform, antibodies, genomics, antibody therapeutics
|
Profile Views: |
5,364 Company Profile Views |
|
|
|
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.
Its full-stack, AI-powered drug discovery platform integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science.
We partner with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development |
|
|
Date |
Type |
Amount |
Investors |
May 4, 2020 |
Unattributed |
$175.6 Million CAD |
Government of Canada under Innovation, Science and Economic Development's (ISED) Strategic Innovation Fund (SIF) |
May 27, 2020 |
Series B |
$105 Million USD |
The financing was led by OrbiMed and current investor DCVC Bio, with an investor syndicate that includes Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly and Company, University of Minnesota, and Presight Capital. |
Dec 11, 2020 |
IPO |
$483 Million USD |
Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets are acting as joint book-running managers for the offering. |
Date |
Type |
Amount |
Investors |
May 4, 2020 |
Unattributed |
$175.6M CAD |
Government of Canada under Innovation, Science and Economic Development's (ISED) Strategic Innovation Fund (SIF) |
May 27, 2020 |
Series B |
$105M USD |
The financing was led by OrbiMed and current investor DCVC Bio, with an investor syndicate that includes Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly and Company, University of Minnesota, and Presight Capital. |
Dec 11, 2020 |
IPO |
$483M USD |
Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets are acting as joint book-running managers for the offering. |
|
|
|
|
|
Jan 27, 2021
|
AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents
|
|
Dec 28, 2020
|
AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico
|
|
Dec 14, 2020
|
Vancouver-based AbCellera Goes Public on Nasdaq with Massive US $555.5M IPO, Company's Market Value Triples to $15.7 Billion on 1st Day
|
|
Dec 2, 2020
|
John Montalbano Joins AbCellera's Board of Directors
|
|
Nov 26, 2020
|
AbCellera and Invetx Expand Multi-Year Antibody Discovery Collaboration in Animal Health
|
|
Nov 25, 2020
|
AbCellera-Discovered Antibody Granted Interim Authorization by Health Canada as a Treatment for COVID-19
|
|
Nov 23, 2020
|
Legendary PayPal and Palantir Co-Founder Peter Thiel Tapped to Join AbCellera’s Board of Directors
|
|
Nov 20, 2020
|
Vancouver-based AbCellera Expands Technology Stack with Acquisition of Trianni for US $90 Million
|
|
Oct 19, 2020
|
AbCellera and IGM Biosciences Announce Multi-Year Antibody Discovery Collaboration
|
|
Oct 15, 2020
|
Fierce Biotech Names Vancouver-based AbCellera Biologics a “Fierce 15” Company of 2020
|
|
|
1 - 10 of 44 results
|
|
 |
|
|
|
Share This Company Profile |
|
|
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
